Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oseltamivir plus short-course high-dose glucocorticoids in newly diagnosed pediatric ITP with poor IVIG response
ChiCTR2300071184Phase 2Not yet recruiting
- Sponsor
- Fujian Children's Hospital
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of oseltamivir in immune thrombocytopenia (ITP) (2 arms), sponsored by Fujian Children's Hospital. Primary endpoints: Platelet count and Bleeding symptoms. Planned start May 2023; status: not yet recruiting.
02
Drugs
oseltamivir
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2300071184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071184.